NCT00947167: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors |
|
|
| Terminated | 2 | 4 | US | pertuzumab, 2C4, Omnitarg, Genentech, erlotinib, Tarceva, Erlotinib hydrochloride | Pamela L. Kunz, Genentech, Inc. | Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma, Pancreatic Neuroendocrine Tumors, Multiple Endocrine Neoplasia | 05/10 | 05/10 | | |
